Back to School: How biopharma can reboot drug development. Access exclusive analysis here

IDM-1: Phase II data; Phase III

Among 17 late stage ovarian cancer patients with minimal residual

Read the full 106 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE